title: The endothelin antagonist bosentan does not improve survival in severe experimental pancreatitis in rats.
abstract: BACKGROUND
  Severity of pancreatitis seems to be aggravated by impairment of vascular perfusion of the gland. Early mortality occurs within the first few days from the acute consequences of pancreatic injury with subsequent inflammatory response. Because vasoactive substances, including endothelin, seem to contribute to early mortality in acute pancreatitis, we tested the hypothesis that the inhibition of endothelin action could alter the outcome after severe experimental pancreatitis.
  
  
  METHODS
  In two groups of rats, pancreatitis was induced by intraductal infusion into the pancreatic duct of 1 microL/g body weight (b.w.) of either a 4% or a 5% sodium taurocholate solution. The mixed endothelin A and endothelin B receptor antagonist bosentan (20 mg/kg b.w.) or vehicle was injected intravenously in 12-h intervals for 3 d starting 1 h after induction of bile acid pancreatitis. This dose of bosentan is known to completely inhibit the effect of exogenous endothelin. The survival rate was monitored for 7 d. Thereafter, the surviving rats were sacrificed and the pancreas was prepared for histological and biochemical evaluation.
  
  
  RESULTS
  Irrespective of the treatment protocol (bosentan versus saline), survival was not different in animals challenged with either 4% or 5% sodium taurocholate. The corresponding survival rates were 62% with bosentan and 77% without bosentan in the 4% sodium taurocholate group. In the 5% sodium taurocholate group, the survival rates were 20% with and 27% without bosentan. Morphological and biochemical alterations were identical in control as well as in endothelin-antagonist-treated rats.
  
  
  CONCLUSIONS
  Therapy with the mixed endothelin A and endothelin B receptor antagonist bosentan does not influence the outcome after severe experimental pancreatitis. Therefore, blockade of endothelin A and B receptor subtypes may not be of major importance as a therapeutic principle in this model of experimental pancreatitis.
authors.affiliation: Institut für Anästhesie, Universität Heidelberg, Mannheim, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Fiedler
authors.forename: D
authors.initials: D
authors.lastname: Ayasse
authors.forename: P
authors.initials: P
authors.lastname: Rohmeiss
authors.forename: N
authors.initials: N
authors.lastname: Gretz
authors.forename: C
authors.initials: C
authors.lastname: Rehbein
authors.forename: V
authors.initials: V
authors.lastname: Keim
mesh_terms: D000818:Animals; D001647:Bile Acids and Salts; D000077300:Bosentan; D016232:Endothelins / Q000037:antagonists & inhibitors*; D005260:Female; D019283:Pancreatitis, Acute Necrotizing / Q000139:chemically induced / Q000401:mortality* / Q000503:physiopathology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides / Q000494:pharmacology*; D013656:Taurocholic Acid; D017211:Treatment Failure
chemical_list: D001647:Bile Acids and Salts; D016232:Endothelins; D013449:Sulfonamides; D013656:Taurocholic Acid; D000077300:Bosentan